JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
123.45
+0.54 (+0.44%)
At close: 4:00PM EDT

123.21 -0.24 (-0.19%)
After hours: 7:59PM EDT

Stock chart is not supported by your current browser
Previous Close122.91
Open122.87
Bid0.00 x 800
Ask0.00 x 1200
Day's Range122.74 - 123.97
52 Week Range121.28 - 148.32
Volume4,940,832
Avg. Volume6,764,069
Market Cap331.111B
Beta0.59
PE Ratio (TTM)260.44
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield3.36 (2.57%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • J&J hit with $21.7 million verdict in another talc asbestos cancer case
    Reuters3 hours ago

    J&J hit with $21.7 million verdict in another talc asbestos cancer case

    Johnson & Johnson (JNJ.N) and its talc suppliers on Wednesday were hit with a $21.7 million jury verdict in a lawsuit by a woman who said she developed cancer after being exposed to asbestos in the company's Baby Powder. The verdict by a Los Angeles jury came down in the case of 68-year-old Joanne Anderson, who was diagnosed with mesothelioma, a form of cancer closely linked to asbestos exposure, and marked the second trial loss for J&J over similar allegations. Of the $21.7 million the jury awarded in compensatory damages, J&J was assigned 67 percent, with the rest distributed among other defendants.

  • Reuters4 hours ago

    J&J hit with $21.7 million verdict in another talc asbestos cancer case

    Johnson & Johnson (JNJ.N) and its talc suppliers on Wednesday were hit with a $21.7 million (£16.2 million) jury verdict in a lawsuit by a woman who said she developed cancer after being exposed to asbestos in the company's Baby Powder. The verdict by a Los Angeles jury came down in the case of 68-year-old Joanne Anderson, who was diagnosed with mesothelioma, a form of cancer closely linked to asbestos exposure, and marked the second trial loss for J&J over similar allegations. Of the $21.7 million the jury awarded in compensatory damages, J&J was assigned 67 percent, with the rest distributed among other defendants.

  • J&J Loses Second Talc-Asbestos Trial and Damages May Grow
    Bloomberg6 hours ago

    J&J Loses Second Talc-Asbestos Trial and Damages May Grow

    Johnson & Johnson lost a second trial linking baby powder use to deadly asbestos cancer and jurors must next decide whether to punish the company on top of their award of $21.7 million in damages. Jurors in state court in California concluded Wednesday J&J was liable for Joanne Anderson’s mesothelioma and awarded the 68-year-old compensatory damages. It’s the second jury in less than two months to conclude J&J sold its iconic baby powder knowing it contained at least trace amounts of asbestos and posed a cancer risk to users.

  • Why Geron Corporation Stock Is Heating Up
    Motley Fool9 hours ago

    Why Geron Corporation Stock Is Heating Up

    Geron's stock is blasting higher this week, but the exact reason isn't clear.

  • Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis
    Zacks12 hours ago

    Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis

    Eli Lilly (LLY) gets FDA approval for label expansion of its psoriasis injection Taltz to include data for psoriasis involving the genital area.

  • Why the world needs more than one Ebola vaccine
    Reuters12 hours ago

    Why the world needs more than one Ebola vaccine

    LONDON (Reuters) - - In the life-and-death race to make the first effective vaccine against Ebola, one company - Merck (MRK.N) - seems bound to win. Immunisations with Merck's VSV EBOV experimental shot began in Congo this week - a big moment in a 40-year fight against a disease that until now could only be tackled by isolation and strict hygiene. Having this vaccine means the world is better placed now than it was in 2014-2016, when the haemorrhagic fever killed more than 11,300 people in history's worst Ebola outbreak in West Africa.

  • Is Fidelity Dividend ETF for Rising Rates (FDRR) a Hot ETF Right Now?
    Zacks12 hours ago

    Is Fidelity Dividend ETF for Rising Rates (FDRR) a Hot ETF Right Now?

    Smart Beta ETF report for FDRR

  • MarketWatch15 hours ago

    Merck’s experimental and unlicensed Ebola vaccine is being used in latest outbreak

    The World Health Organization has started to vaccinate thousands of people considered at high risk of contacting the infectious and often-deadly disease Ebola in the Democratic Republic of Congo. The WHO said Monday it is working with NGOs and community leaders to administer an experimental vaccine that was studied in a trial in Guinea in 2015, but has not yet been used to contain a major outbreak. Most are in a remote town, but there are four confirmed cases in Mbandaka, the provincial capital which has a population of more than 1 million people.

  • Is This Stock the Next Biotech Acquisition Target?
    Motley Foolyesterday

    Is This Stock the Next Biotech Acquisition Target?

    Optimism is growing that this cancer drug developer will be the next biotech to be acquired.

  • JNJ’s Baby Care Line Set for Relaunch to Stimulate Falling Sales
    Market Realistyesterday

    JNJ’s Baby Care Line Set for Relaunch to Stimulate Falling Sales

    Thus, the company has announced its plans to make some changes in its baby care product line and is set for a relaunch with a target of more naturally sourced products with recyclable packaging. The redesigned line is expected to launch in August. Johnson & Johnson is planning an end-to-end relaunch. Johnson & Johnson recognizes the need to make certain fundamental changes to its products after witnessing declining sales from its leading range of baby care products.

  • How Are Tesaro’s Valuations and Cash Flows?
    Market Realistyesterday

    How Are Tesaro’s Valuations and Cash Flows?

    Tesaro used $147.6 million in operating activities in the first quarter—compared to $114.6 million in the first quarter of 2017. The company used $1.6 million in investing activities in the first quarter—compared to $1.8 million in the first quarter of 2017. The expense was mainly for purchasing property and equipment related to Tesaro expanding leased premises at its headquarters.

  • Wall Street Sees Upside of More than 17% for JNJ in the Next Year
    Market Realistyesterday

    Wall Street Sees Upside of More than 17% for JNJ in the Next Year

    Over the last few quarters, Johnson & Johnson (JNJ) has seen a number of factors affecting investor sentiments surrounding its stock. The company, however, posted strong results for the first quarter on April 17, exceeding analysts’ estimates. In this article, we’ll take a look at analysts’ recommendations on JNJ for the next 12 months.

  • Gauging the Upside Potential of Vertex Pharmaceuticals Stock
    Market Realist2 days ago

    Gauging the Upside Potential of Vertex Pharmaceuticals Stock

    Vertex Pharmaceuticals (VRTX) is focused on developing and bringing to market therapies for treating cystic fibrosis (or CF) and advancing research and development programs for other diseases. Of the 25 analysts covering Vertex Pharmaceuticals in May, 21 of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.76 with a target price of $191.39, implying an upside of 22.6% over its closing price of $156.16 on May 16. Of the 26 analysts covering Gilead Sciences (GILD) in May, 16 of them have given the stock a “buy” or higher rating, and ten have given it a “hold.” The mean rating for the stock is 2.15 with a target price of $85.81.

  • Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval
    Zacks2 days ago

    Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval

    Glaxo (GSK) and partner J&J (JNJ) gain marketing approval in the EU for Juluca, a two-drug HIV treatment.

  • Roche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018
    Market Realist2 days ago

    Roche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018

    Roche’s (RHHBY) MabThera/Rituxan reported revenues of 1.7 billion Swiss francs in the first quarter compared to 1.9 billion Swiss francs in the first quarter of 2017, which reflected a decline of ~8% YoY (year-over-year) on constant exchange rate basis.

  • Chinese investors lead another monster round into this early cancer detection company
    American City Business Journals2 days ago

    Chinese investors lead another monster round into this early cancer detection company

    The Menlo Park company had already raised $1.2 billion; now it's adding $300 million, mainly from Chinese investors, as it aims to develop a simple blood test to discover cancers early.

  • TheStreet.com2 days ago

    How to Play the Long Side of Johnson & Johnson

    In this daily bar chart of JNJ, below, we can see that prices for JNJ have been under selling pressure since late January. In the bottom panel is the 12-day price momentum study which shows a pattern of rising lows from February to March to April. In this weekly bar chart of JNJ, below, we have a mixed picture.

  • InvestorPlace2 days ago

    It’s Not as Bad as It Looks for Johnson & Johnson Stock

    It’s been a bumpy ride so far this year for pharmaceutical giant Johnson & Johnson (NYSE:JNJ). Johnson & Johnson has been weighed down by poor sentiment in the healthcare space, legal troubles and worries about further government interference in the industry. One such concern has been Johnson & Johnson’s Baby Care unit.

  • InvestorPlace3 days ago

    7 ‘Blue-Chip Stocks’ That Aren’t Blue Chips at All

    A lot of large-cap familiar names are still called “blue-chip stock” when they are nothing of the kind. If you can’t rid the term “blue-chip stock” from your lexicon, then it should at least apply to a whole new stream of companies. “Blue-chip stock” used to refer to companies that were constantly growing earnings in the high single-digits or more in terms of percentage, had a fortress balance sheet and were constantly innovating.

  • 3 Days Left To Cash In On Johnson & Johnson (NYSE:JNJ) Dividend, Is It Worth Buying?
    Simply Wall St.3 days ago

    3 Days Left To Cash In On Johnson & Johnson (NYSE:JNJ) Dividend, Is It Worth Buying?

    Have you been keeping an eye on Johnson & Johnson’s (NYSE:JNJ) upcoming dividend of $0.9 per share payable on the 12 June 2018? Then you only have 3 days leftRead More...

  • Benzinga3 days ago

    The Week Ahead In Biotech: PDUFA Dates, IPOs And More

    Some M&A activity , earnings news flow and clinical trial outcomes helped the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) preserve gains this week. As the earnings season winds down, here're ...

  • A Look into Roche Holding’s Performance in Q1 2018
    Market Realist3 days ago

    A Look into Roche Holding’s Performance in Q1 2018

    In the first quarter, Roche Holding (RHHBY) reported revenues of ~13.6 billion Swiss francs compared to ~12.9 billion Swiss francs in the first quarter of 2017, which reflected ~5.0% growth on a YoY (year-over-year) basis.

  • Reuters3 days ago

    Congo to begin Ebola vaccinations on Monday

    H ealth workers in Democratic Republic of Congo will begin a vaccination campaign on Monday aimed at containing an outbreak of the deadly Ebola virus, a spokeswoman for the health ministry said. Jessica Ilunga said 4,000 doses of vaccine were shipped on Saturday to Mbandaka, which last week registered the first cases in an urban area since the latest flare-up of the disease was announced earlier this month.

  • Reuters5 days ago

    Congo's Ebola not an international emergency, can be controlled -WHO

    GENEVA/KINSHASA, May 18 (Reuters) - The Ebola outbreak in Democratic Republic of Congo can be brought under control and is not an international public health emergency, experts advising the World Health Organization said on Friday. Earlier in the day the WHO had said the first confirmation of Ebola in Mbandaka, a city of about 1.5 million people, had prompted it to declare a "very high" public health risk to the country and a "high" risk to the region.